The Evolution of Open-Label Extensions and Rare Disease Studies

When running early development studies, sponsors must consider whether orCovance Employees in Lab Rare Disease Studies not to provide open-label, long-term treatment at the end of their randomized, placebo-controlled trial. In the past, sponsors have been hesitant to offer open-label extensions. But with our industry’s increasing focus on patient-centric care, sponsors are now weighing their options to incorporate more patient input into early development, especially when working with promising novel treatments in rare disease studies.

Continue reading